• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2012 Product Image

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2012

  • ID: 2245282
  • September 2012
  • 345 pages
  • Global Markets Direct

Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD). Graft Versus Host Disease (GVHD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Graft Versus Host Disease (GVHD).
- A review of READ MORE >

2
List of Tables 7
List of Figures 8
Introduction 10
REPORT COVERAGE 10
Graft Versus Host Disease (GVHD) Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Graft Versus Host Disease (GVHD) 12
Graft Versus Host Disease (GVHD) Therapeutics under Development by Companies 14
Graft Versus Host Disease (GVHD) Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Graft Versus Host Disease (GVHD) Therapeutics – Products under Development by Companies 26
Graft Versus Host Disease (GVHD) Therapeutics – Products under Investigation by Universities/Institutes 27
Companies Involved in Graft Versus Host Disease (GVHD) Therapeutics Development 36
Osiris Therapeutics, Inc. 36
Athersys, Inc. 37
Rigel Pharmaceuticals, Inc. 38
IMMUNOMEDICS, INC 39
Accentia Biopharmaceuticals, Inc. 40
Jazz Pharmaceuticals, Inc. 41
Soligenix, Inc. 42
NeoStem, Inc. 43
Cytomedix, Inc. 44
JCR Pharmaceuticals Co., Ltd. 45
MediPost Co., Ltd. 46
Alder Biopharmaceuticals Inc. 47
Lumen Therapeutics 48
Adeona Pharmaceuticals, Inc. 49
Kiadis Pharma B.V. 50
CBio Limited 51
Bellicum Pharmaceuticals, Inc. 52
REGiMMUNE Corporation 53
ADIENNE Pharma & Biotech 54
Dr. Falk Pharma GmbH 55
Lycera Corp. 56
Sigmoid Pharma. 57
Graft Versus Host Disease (GVHD) – Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Combination Products 59
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 65
MultiStem - Drug Profile 65
remestemcel-L - Drug Profile 67
milatuzumab - Drug Profile 69
ATIR - Drug Profile 70
Rhitol - Drug Profile 71
beclomethasone dipropionate - Drug Profile 72
clazakizumab - Drug Profile 74
JR-031 - Drug Profile 76
cyclophosphamide - Drug Profile 77
Anti-CD4 802-2 - Drug Profile 79
Promostem - Drug Profile 80
inolimomab - Drug Profile 81
LT-1951 - Drug Profile 82
Mycophenolate + Corticosteroids - Drug Profile 84
imatinib mesylate - Drug Profile 85
Velcade + Tacrolimus + Methotrexate + Blood Stem Cell Transplantation - Drug Profile 86
sirolimus - Drug Profile 87
Prograf + Rapamune + Velcade - Drug Profile 88
Pentostatin + Tacrolimus + Methotrexate - Drug Profile 89
Maraviroc + Allogeneic Stem Cell Transplantation - Drug Profile 90
XToll - Drug Profile 91
aldesleukin - Drug Profile 93
aldesleukin - Drug Profile 95
Busulfan + Fludarabine + Cytoxan + Bone Marrow Transplantation - Drug Profile 96
Allogenic Mesenchymal Stem Cells + Prednisone + Cyclosporine - Drug Profile 98
Tacrolimus + Sirolimus - Drug Profile 100
Dexamethasone + Tacrolimus - Drug Profile 102
rituximab - Drug Profile 103
bortezomib - Drug Profile 104
sirolimus - Drug Profile 105
Tacrolimus + Mycophenolate Mofetil + Sirolimus - Drug Profile 106
etanercept - Drug Profile 108
Prograf + Methotrexate - Drug Profile 110
budesonide - Drug Profile 111
Therapeutic allogeneic lymphocytes program - Drug Profile 113
Natural Killer Cells - Drug Profile 114
etanercept - Drug Profile 115
Allogeneic Mesenchymal Stem Cells - Drug Profile 116
Nipent + Cellcept + Sandimmune + Allolymph - Drug Profile 117
Everolimus + Mycophenolate Sodium - Drug Profile 119
RGI-2001 - Drug Profile 120
Tacrolimus + Mycophenolate + Peripheral Stem Cell Transplantation + Radiation Therapy - Drug Profile 121
tocilizumab - Drug Profile 123
Cyclophosphamide + Fludarabine + Anti-Thymocyte Globulin + Cyclosporine + Peripheral Blood Stem Cell Transplantation + Therapeutic Allogeneic Lymphocytes - Drug Profile 124
Fludarabine + Cyclosporine + Cytarabine + Filgrastim + Idarubicin + Methylprednisolone + Peripheral Stem Cell Transplantation - Drug Profile 126
Simulect + Cyclosporine - Drug Profile 128
Fludarabine + Busulfan + Tacrolimus + Mycophenolate + Vorinostat + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 129
pentostatin - Drug Profile 131
Mycophenolate Mofetil + Prednisone - Drug Profile 132
rifaximin - Drug Profile 133
Velcade + Prednisone - Drug Profile 134
Visilizumab + Tacrolimus + Methotrexate - Drug Profile 135
Methotrexate + Methylprednisolone - Drug Profile 136
Anti-Thymocyte Globulin + Busulfan + Cyclosporine + Melphalan + Methylprednisolone + Umbilical Cord Blood Transplantation +Radiation Therapy - Drug Profile 137
Methylprednisolone + Extracorporeal Photopheresis - Drug Profile 139
Tacrolimus + Sirolimus + G-CSF + Antithymocyte globulin/Thymoglobulin + Fludarabine + Melphalan + Unrelated Cord Blood Transplantation - Drug Profile 140
Busulfan + Fludarabine + Cyclophosphamide - Drug Profile 142
Fludara + Alkeran + Cyclosporine + Methotrexate + Allogeneic Non-Myeloablative Stem Cell Transplantation - Drug Profile 143
Sirolimus + Prednisone - Drug Profile 144
sirolimus - Drug Profile 145
ApoCell - Drug Profile 146
Tacrolimus + Methotrexate - Drug Profile 147
Cyclosporine + Mycophenolate Mofetil + Methotrexate - Drug Profile 149
Tacrolimus + Sirolimus + Methotrexate - Drug Profile 151
imatinib mesylate - Drug Profile 153
Anti-thymocyte globulin + Busulfan + Cyclosporine + Melphalan + Methotrexate + Methylprednisolone + Stem Cell Transplantation - Drug Profile 154
Abatacept + Cyclosporine + Methotrexate - Drug Profile 156
cyclosporine - Drug Profile 158
Fludarabine + Mycophenolate Mofetil + Cyclosporine + Allogeneic Bone Marrow Transplantation + Radiation Therapy - Drug Profile 159
Cyclophosphamide + Anti-Thymocyte Globulin + Cyclosporine + Methotrexate + Donor Bone Marrow Transplantation - Drug Profile 161
dexamethasone acetate - Drug Profile 163
Pentostatin + Corticosteroids - Drug Profile 165
Fludarabine + Cyclophosphamide + Cyclosporine + Allogeneic Lymphocytes + Peripheral Blood Stem Cell Transplantation + Allogeneic Hematopoietic Stem Cell Transplantation + Total Body Irradiation - Drug Profile 167
Etanercept + Corticosteroids - Drug Profile 169
Anti-Thymocyte Globulin + Busulfan + Fludarabine Phosphate + Allogeneic Bone Marrow Transplantation - Drug Profile 171
Anti-Lymphocyte Globulin + Busulfan + Fludarabine + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 172
Coritcosteroid + Ontak - Drug Profile 174
Tacrolimus + Mycophenolate Mofetil + Fludarabine + Peripheral Stem Cell Transplantation + Radiation Therapy - Drug Profile 175
Fludarabine + Busulfan + Thymoglobulin + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 177
Infliximab + Basiliximab - Drug Profile 179
Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Stem Cell Transplantation + Campath + Rapamune + Cytoxan - Drug Profile 180
Busulfex + Melphalan + Methotrexate + Tacrolimus + Allogeneic Bone Marrow Transplantation - Drug Profile 182
mycophenolate mofetil - Drug Profile 183
Alpha-1 Antitrypsin - Drug Profile 185
Cyclophosphamide + Anti Thymocyte Globulin + Cyclosporine + Methylprednisolone + Busulphan + G-CSF + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 187
Busulfan + Cyclophosphamide + Anti-Thymocyte Globulin + Tacrolimus + Mycophenolate Mofetil + Stem Cell Transplantation - Drug Profile 189
Fludarabine + Thiotepa + Tacrolimus + Allogeneic Blood Stem Cell Transplantation - Drug Profile 191
Busulfan + Fludarabine + Anti Thymocyte Globulin + Tacrolimus + Methotrexate + Donor Lymphocyte Infusions + Allogeneic Stem Cell Transplantation - Drug Profile 193
Tacrolimus + Mycophenolate + Etanercept + Methoxsalen + Stem Cell Transplant - Drug Profile 195
Rituximab + Mycophenolate Mofetil + Tacrolimus + Anti-Thymocyte Globulin + Cyclophosphamide + Fludarabine Phosphate + Busulfan + Stem Cell Transplantation + Radiation Therapy - Drug Profile 197
Allodepleted T Cells - Drug Profile 200
Thymoglobulin - Drug Profile 201
Thymoglobulin + Radiation Therapy + Allogeneic Peripheral Blood Stem Cell Transplantation - Drug Profile 203
mycophenolate mofetil - Drug Profile 204
Bortezomib + Fludarabine phosphate + Melphalan + Tacrolimus + Sirolimus + Allogeneic Hematopoietic Stem Cell Transplantation + Radiation Therapy - Drug Profile 205
Tacrolimus + Sirolimus - Drug Profile 208
cyclosporine - Drug Profile 209
tacrolimus - Drug Profile 210
Methotrexate + Tacrolimus - Drug Profile 211
Pentostatin + Tacrolimus + Sirolimus + Cyclophosphamide - Drug Profile 212
Basiliximab + Cyclosporine - Drug Profile 214
Therapeutic Allogeneic Lymphocytes + Cyclophosphamide + Cyclosporine + Fludarabine Phosphate + Tacrolimus + Radiation Therapy + Peripheral Blood Stem Cell Allotransplantation - Drug Profile 215
Allogeneic Stem Cell Transplantation - Drug Profile 217
Ara-C + Cytoxan + Mesna + Campath + Radiation Therapy - Drug Profile 219
atorvastatin calcium - Drug Profile 221
Cyclosporine + Fludarabine + Methotrexate + Mycophenolate Mofetil + Tacrolimus + Treosulfan + Anti-Thymocyte Globulin + Stem Cell Transplantation + Radiation Therapy - Drug Profile 222
Therapeutic Allogeneic Lymphocytes + Cyclosporine + Mycophenolate Mofetil + Pentostatin - Drug Profile 225
Cyclophosphamide + Cyclosporine + Methotrexate + Allogeneic bone marrow transplantation + Stem cell transplantation - Drug Profile 227
Cyclophosphamide + Fludarabine Phosphate + Total-body Irradiation + Hematopoietic Cell Transplantation - Drug Profile 229
pomalidomide - Drug Profile 231
leucyl-leucine-methyl ester - Drug Profile 232
Rituximab + Cyclosporine + Prednisone - Drug Profile 233
Sirolimus + Extracorporeal Photopheresis + Prednisone - Drug Profile 234
Sirolimus + Mycophenolate Mofetil - Drug Profile 236
Sirolimus + Mycophenolate Mofetil - Drug Profile 237
Bortezomib + Lenalidomide - Drug Profile 239
Aldesleukin + Recombinant Interferon Gamma + Busulfan + Cyclophosphamide + Cyclosporine + Radiation Therapy - Drug Profile 240
Anti-Thymocyte Globulin + Busulfan + Cyclophosphamide + Cyclosporine + Melphalan + Methylprednisolone + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 242
Busulfan + Cyclophosphamide + Thymoglobulin + Tacrolimus + Mycophenolate Mofetil + Stem Cell Transplantation - Drug Profile 244
Anti-Thymocyte Globulin + Busulfan + Cyclosporine + Melphalan + Methylprednisolone + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 246
Anti-Thymocyte Globulin + Busulfan + Fludarabine Phosphate + Methotrexate + Tacrolimus - Drug Profile 248
Anti-Thymocyte Globulin + G-CSF + Busulfan + Cyclophosphamide + Cyclosporine + Methylprednisolone + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 251
Methotrexate + Cyclosporine A - Drug Profile 253
HSVTK Retrovirally-Transduced Donor T Lymphocytes - Drug Profile 254
PKC Theta Inhibitor Program - Drug Profile 255
alefacept - Drug Profile 256
cyclosporine - Drug Profile 257
Mesenchymal stem cells - Drug Profile 258
Methotrexate + Sirolimus + Tacrolimus - Drug Profile 260
pentostatin - Drug Profile 262
rituximab - Drug Profile 263
Tacrolimus + Thymoglobulin - Drug Profile 264
Fludarabine + Sirolimus + Cyclosporine + Mycophenolate Mofetil + Radiation Therapy + Allogeneic Peripheral Blood Stem Cell Transplantation - Drug Profile 265
Mycophenolate Mofetil + Fludarabine + Tacrolimus + Sirolimus + Peripheral Blood Stem Cell Transplantation + Radiation Therapy - Drug Profile 267
Mycophenolate Mofetil + Fludarabine + Tacrolimus + Stem Cell Transplantation + Radiation Therapy - Drug Profile 269
Methotrexate + Tacrolimus + Sirolimus + Cyclophosphamide - Drug Profile 271
rituximab - Drug Profile 273
Allogenic Mesenchymal Stem Cells - Drug Profile 274
Busulfan + Cyclophosphamide + Fludarabine + Umbilical Cord Blood Transplant - Drug Profile 275
Prednisone + Cyclosporin/Tacrolimus + Allogenic mesenchymal stem cells - Drug Profile 277
cyclophosphamide - Drug Profile 279
CaspaCIDE ASC - Drug Profile 280
Sirolimus + Prednisone - Drug Profile 281
Recombinant ILT3-Fc - Drug Profile 283
Homeo-GH - Drug Profile 285
Hematopoietic Stem Cell Transplantation + Cyclophosphamide - Drug Profile 286
Rituximab + Cyclophosphamide + Fludarabine + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 287
Bioenergetics Program - Drug Profile 289
Bz-423 - Drug Profile 290
Athelos - Drug Profile 291
CT-112 - Drug Profile 292
Brentuximab Vedotin - Drug Profile 293
ImmuStem - Drug Profile 294
Drug For Graft Versus Host Disease - Drug Profile 295
Allogenic Mesenchymal Stem Cells - Drug Profile 296
Graft Versus Host Disease (GVHD) Therapeutics – Drug Profile Updates 298
Graft Versus Host Disease (GVHD) Therapeutics – Discontinued Products 315
Graft Versus Host Disease (GVHD) Therapeutics - Dormant Products 317
Graft Versus Host Disease (GVHD) – Product Development Milestones 323
Featured News & Press Releases 323
Appendix 334
Methodology 334
Coverage 334
Secondary Research 334
Primary Research 334
Expert Panel Validation 334
Contact Us 335
Disclaimer 335

List of Tables
Number of Products Under Development for Graft Versus Host Disease (GVHD), H2 2012 22
Products under Development for Graft Versus Host Disease (GVHD) – Comparative Analysis, H2 2012 23
Number of Products under Development by Companies, H2 2012 25
Number of Products under Development by Companies, H2 2012 (Contd..1) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 30
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 31
Comparative Analysis by Late Stage Development, H2 2012 32
Comparative Analysis by Mid Clinical Stage Development, H2 2012 33
Comparative Analysis by Early Clinical Stage Development, H2 2012 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 35
Products under Development by Companies, H2 2012 36
Products under Investigation by Universities/Institutes, H2 2012 37
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 40
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 41
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 42
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 43
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 44
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 45
Osiris Therapeutics, Inc., H2 2012 46
Athersys, Inc., H2 2012 47
Rigel Pharmaceuticals, Inc., H2 2012 48
IMMUNOMEDICS, INC, H2 2012 49
Accentia Biopharmaceuticals, Inc., H2 2012 50
Jazz Pharmaceuticals, Inc., H2 2012 51
Soligenix, Inc., H2 2012 52
NeoStem, Inc., H2 2012 53
Cytomedix, Inc., H2 2012 54
JCR Pharmaceuticals Co., Ltd., H2 2012 55
MediPost Co., Ltd., H2 2012 56
Alder Biopharmaceuticals Inc., H2 2012 57
Lumen Therapeutics, H2 2012 58
Adeona Pharmaceuticals, Inc., H2 2012 59
Kiadis Pharma B.V., H2 2012 60
CBio Limited, H2 2012 61
Bellicum Pharmaceuticals, Inc., H2 2012 62
REGiMMUNE Corporation, H2 2012 63
ADIENNE Pharma & Biotech, H2 2012 64
Dr. Falk Pharma GmbH, H2 2012 65
Lycera Corp., H2 2012 66
Sigmoid Pharma., H2 2012 67
Assessment by Monotherapy Products, H2 2012 68
Assessment by Combination Products, H2 2012 69
Assessment by Stage and Route of Administration, H2 2012 71
Assessment by Stage and Molecule Type, H2 2012 74
Graft Versus Host Disease (GVHD) Therapeutics – Drug Profile Updates 308
Graft Versus Host Disease (GVHD) Therapeutics – Discontinued Products 325
Graft Versus Host Disease (GVHD) Therapeutics – Discontinued Products (Contd..1) 326
Graft Versus Host Disease (GVHD) Therapeutics – Dormant Products 327
Graft Versus Host Disease (GVHD) Therapeutics – Dormant Products (Contd..1) 328
Graft Versus Host Disease (GVHD) Therapeutics – Dormant Products (Contd..2) 329
Graft Versus Host Disease (GVHD) Therapeutics – Dormant Products (Contd..3) 330
Graft Versus Host Disease (GVHD) Therapeutics – Dormant Products (Contd..4) 331
Graft Versus Host Disease (GVHD) Therapeutics – Dormant Products (Contd..5) 332

List of Figures
Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2012 22
Products under Development for Graft Versus Host Disease (GVHD) – Comparative Analysis, H2 2012 23
Products under Development by Companies, H2 2012 24
Products under Investigation by Universities/Institutes, H2 2012 27
Late Stage Products, H2 2012 32
Mid Clinical Stage Products, H2 2012 33
Early Clinical Stage Products, H2 2012 34
Discovery and Pre-Clinical Stage Products, H2 2012 35
Assessment by Monotherapy Products, H2 2012 68
Assessment by Combination Products, H2 2012 69
Assessment by Route of Administration, H2 2012 70
Assessment by Stage and Route of Administration, H2 2012 71
Assessment by Molecule Type, H2 2012 72
Assessment by Stage and Molecule Type, H2 2012 73

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos